Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed Phase 0/B)

NCT03647657 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT03647657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03647657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer (Lumed Phase 0/B)
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 1
Overall status
Completed
Start date
December 13, 2018
Completion date
December 14, 2021
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer, medullary